NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Aadi Bioscience reported first quarter 2022 financial results and provided a corporate update.
Aadi Bioscience reported FYARRO net product sales of $2.3 million in the first quarter of 2022, following its launch in February. The company's cash and cash equivalents totaled $129.8 million as of March 31, 2022. Net loss for the quarter was $13.9 million.
- FYARRO net product sales were $2.3 million in partial first quarter.
- First patient was dosed in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or TSC2 altered solid tumors.
- Aadi was granted a product-specific permanent J-code (J9331) for FYARRO that will become effective on July 1, 2022.
- Aadi announced a partnership with NGS providers and leaders in genomic testing and profiling, including Foundation Medicine, Tempus and others, to assist with identifying patients for its PRECISION 1 trial.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$2.31M
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
Aadi cautions that certain statements included in the press release are forward-looking statements based on current beliefs and expectations.
Tailwinds
- Plans and potential for success relating to commercializing FYARRO.
- Expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of FYARRO.
- Plans related to further development and manufacturing of FYARRO.
- Anticipated reception of FYARRO in the physician community.
- Sufficiency of existing capital resources and the expected timeframe to fund future operating expenses and capital expenditure requirements.
Headwinds
- Risks related to Aadi’s ability to successfully commercialize FYARRO.
- Risks related to reimbursement and pricing of FYARRO.
- Uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications, including potential delays in the commencement, enrollment and completion of clinical trials for additional indications.
- The risk that unforeseen adverse reactions or side effects may occur in the course of commercializing, developing and testing FYARRO.
- Risks related to the impact of the COVID-19 pandemic on Aadi’s operations, the biotechnology industry and the economy generally.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro